vs
Side-by-side financial comparison of Fresenius Medical Care AG (FMS) and Progyny, Inc. (PGNY). Click either name above to swap in a different company.
Fresenius Medical Care AG is the larger business by last-quarter revenue ($5.5B vs $318.4M, roughly 17.2× Progyny, Inc.). Fresenius Medical Care AG runs the higher net margin — 7.9% vs 3.9%, a 4.0% gap on every dollar of revenue. On growth, Progyny, Inc. posted the faster year-over-year revenue change (6.7% vs -0.3%).
Fresenius Medical Care AG & Co. KGaA is a German healthcare company which provides kidney dialysis services through a network of 4,171 outpatient dialysis centers, serving 345,425 patients. The company primarily treats end-stage renal disease (ESRD), which requires patients to undergo dialysis 3 times per week for the rest of their lives.
Progyny, Inc. is a leading fertility and family building benefits provider operating primarily in the United States. It partners with employers to offer benefits including in vitro fertilization, fertility preservation, adoption assistance, and surrogacy support, serving millions of members across diverse industry segments.
FMS vs PGNY — Head-to-Head
Income Statement — Q4 2025 vs Q4 2025
| Metric | | |
|---|---|---|
| Revenue | $5.5B | $318.4M |
| Net Profit | $434.2M | $12.5M |
| Gross Margin | 27.4% | 24.1% |
| Operating Margin | 11.7% | 4.8% |
| Net Margin | 7.9% | 3.9% |
| Revenue YoY | -0.3% | 6.7% |
| Net Profit YoY | 240.4% | 18.5% |
| EPS (diluted) | — | $0.14 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $5.5B | $318.4M | ||
| Q3 25 | — | $313.3M | ||
| Q2 25 | — | $332.9M | ||
| Q1 25 | — | $324.0M | ||
| Q4 24 | $5.5B | $298.4M | ||
| Q3 24 | — | $286.6M | ||
| Q2 24 | — | $304.1M | ||
| Q1 24 | — | $278.1M |
| Q4 25 | $434.2M | $12.5M | ||
| Q3 25 | — | $13.9M | ||
| Q2 25 | — | $17.1M | ||
| Q1 25 | — | $15.1M | ||
| Q4 24 | $127.6M | $10.5M | ||
| Q3 24 | — | $10.4M | ||
| Q2 24 | — | $16.5M | ||
| Q1 24 | — | $16.9M |
| Q4 25 | 27.4% | 24.1% | ||
| Q3 25 | — | 23.2% | ||
| Q2 25 | — | 23.7% | ||
| Q1 25 | — | 23.4% | ||
| Q4 24 | 25.0% | 21.3% | ||
| Q3 24 | — | 20.7% | ||
| Q2 24 | — | 22.5% | ||
| Q1 24 | — | 22.4% |
| Q4 25 | 11.7% | 4.8% | ||
| Q3 25 | — | 6.9% | ||
| Q2 25 | — | 7.3% | ||
| Q1 25 | — | 7.5% | ||
| Q4 24 | 5.1% | 5.3% | ||
| Q3 24 | — | 4.3% | ||
| Q2 24 | — | 6.8% | ||
| Q1 24 | — | 6.7% |
| Q4 25 | 7.9% | 3.9% | ||
| Q3 25 | — | 4.4% | ||
| Q2 25 | — | 5.1% | ||
| Q1 25 | — | 4.6% | ||
| Q4 24 | 2.3% | 3.5% | ||
| Q3 24 | — | 3.6% | ||
| Q2 24 | — | 5.4% | ||
| Q1 24 | — | 6.1% |
| Q4 25 | — | $0.14 | ||
| Q3 25 | — | $0.15 | ||
| Q2 25 | — | $0.19 | ||
| Q1 25 | — | $0.17 | ||
| Q4 24 | — | $0.12 | ||
| Q3 24 | — | $0.11 | ||
| Q2 24 | — | $0.17 | ||
| Q1 24 | — | $0.17 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.7B | $112.2M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $15.4B | $516.0M |
| Total Assets | $33.5B | $742.4M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.7B | $112.2M | ||
| Q3 25 | — | $134.0M | ||
| Q2 25 | — | $132.5M | ||
| Q1 25 | — | $109.2M | ||
| Q4 24 | $1.3B | $162.3M | ||
| Q3 24 | — | $91.5M | ||
| Q2 24 | — | $95.0M | ||
| Q1 24 | — | $115.0M |
| Q4 25 | $15.4B | $516.0M | ||
| Q3 25 | — | $560.0M | ||
| Q2 25 | — | $515.0M | ||
| Q1 25 | — | $467.2M | ||
| Q4 24 | $17.0B | $422.1M | ||
| Q3 24 | — | $434.9M | ||
| Q2 24 | — | $456.2M | ||
| Q1 24 | — | $571.6M |
| Q4 25 | $33.5B | $742.4M | ||
| Q3 25 | — | $795.2M | ||
| Q2 25 | — | $761.0M | ||
| Q1 25 | — | $730.3M | ||
| Q4 24 | $36.3B | $607.1M | ||
| Q3 24 | — | $660.0M | ||
| Q2 24 | — | $698.6M | ||
| Q1 24 | — | $794.3M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $2.9B | $54.2M |
| Free Cash FlowOCF − Capex | — | $48.6M |
| FCF MarginFCF / Revenue | — | 15.3% |
| Capex IntensityCapex / Revenue | — | 1.8% |
| Cash ConversionOCF / Net Profit | 6.67× | 4.34× |
| TTM Free Cash FlowTrailing 4 quarters | — | $191.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.9B | $54.2M | ||
| Q3 25 | — | $50.7M | ||
| Q2 25 | — | $55.5M | ||
| Q1 25 | — | $49.8M | ||
| Q4 24 | $2.6B | $52.2M | ||
| Q3 24 | — | $44.5M | ||
| Q2 24 | — | $56.7M | ||
| Q1 24 | — | $25.7M |
| Q4 25 | — | $48.6M | ||
| Q3 25 | — | $46.0M | ||
| Q2 25 | — | $50.2M | ||
| Q1 25 | — | $47.0M | ||
| Q4 24 | — | $50.3M | ||
| Q3 24 | — | $42.7M | ||
| Q2 24 | — | $55.8M | ||
| Q1 24 | — | $24.9M |
| Q4 25 | — | 15.3% | ||
| Q3 25 | — | 14.7% | ||
| Q2 25 | — | 15.1% | ||
| Q1 25 | — | 14.5% | ||
| Q4 24 | — | 16.8% | ||
| Q3 24 | — | 14.9% | ||
| Q2 24 | — | 18.4% | ||
| Q1 24 | — | 8.9% |
| Q4 25 | — | 1.8% | ||
| Q3 25 | — | 1.5% | ||
| Q2 25 | — | 1.6% | ||
| Q1 25 | — | 0.9% | ||
| Q4 24 | — | 0.6% | ||
| Q3 24 | — | 0.6% | ||
| Q2 24 | — | 0.3% | ||
| Q1 24 | — | 0.3% |
| Q4 25 | 6.67× | 4.34× | ||
| Q3 25 | — | 3.65× | ||
| Q2 25 | — | 3.24× | ||
| Q1 25 | — | 3.31× | ||
| Q4 24 | 20.20× | 4.95× | ||
| Q3 24 | — | 4.27× | ||
| Q2 24 | — | 3.44× | ||
| Q1 24 | — | 1.52× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FMS
Segment breakdown not available.
PGNY
| Fertility Benefit Services | $208.6M | 66% |
| Pharmacy Benefit Services | $109.8M | 34% |
